Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA–induced dopaminergic denervation

In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin

(2016) Matteo Santoro et al.   NEUROBIOLOGY OF DISEASE

Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-β Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus

(2016) Yan Hong et al.   NEUROCHEMICAL RESEARCH

RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis

(2016) Rashmi Ray et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

A partial lesion model of Parkinson's disease in mice – Characterization of a 6-OHDA-induced medial forebrain bundle lesion

(2015) Jordi Boix et al.   BEHAVIOURAL BRAIN RESEARCH

Increased tau phosphorylation and receptor for advanced glycation endproducts (RAGE) in the brain of mice infected with Leishmania amazonensis

(2015) Juciano Gasparotto et al.   BRAIN BEHAVIOR AND IMMUNITY

Altered morphological dynamics of activated microglia after induction of status epilepticus

(2015) Elena Avignone et al.   Journal of Neuroinflammation

Receptor for Advanced Glycation End-Product Antagonist Reduces Blood-Brain Barrier Damage After Intracerebral Hemorrhage

(2015) F. Yang et al.   STROKE

Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis

(2015) Judyta K. Juranek et al.   Frontiers in Cellular Neuroscience

Neuroinflammation in Parkinson’s disease and its potential as therapeutic target

(2015) Qinqin Wang et al.   Translational Neurodegeneration

Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress

(2014) Julio Tobon-Velasco et al.   CNS & Neurological Disorders-Drug Targets

Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury

(2014) Hongju Zhang et al.   Cell Death & Disease

Cellular signalling of the receptor for advanced glycation end products (RAGE)

(2013) Jianling Xie et al.   CELLULAR SIGNALLING

Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats

(2013) Michelle Healy-Stoffel et al.   NEUROSCIENCE LETTERS

Probucol Increases Striatal Glutathione Peroxidase Activity and Protects against 3-Nitropropionic Acid-Induced Pro-Oxidative Damage in Rats

(2013) Dirleise Colle et al.   PLoS One

S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway

(2012) Kinnari Sathe et al.   BRAIN

Motor and Non-Motor Features of Parkinson’s Disease – A Review of Clinical and Experimental Studies

(2012) Marcelo M.S. Lima et al.   CNS & Neurological Disorders-Drug Targets

A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease

(2012) Rashid Deane et al.   JOURNAL OF CLINICAL INVESTIGATION

Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity

(2012) Peter Teismann et al.   NEUROBIOLOGY OF AGING

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

(2012) Sherri L. Thiele et al.   Jove-Journal of Visualized Experiments

Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson’s disease

(2010) Shane Grealish et al.   EUROPEAN JOURNAL OF NEUROSCIENCE

Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine

(2010) Ronise M. Santiago et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Inflammation and the Redox-sensitive AGE-RAGE Pathway as a Therapeutic Target in Alzheimer's Disease

(2008) Annette Maczurek et al.   Annals of the New York Academy of Sciences